SAR97276A

DRUG2 trials

Sponsors

Sanofi

Conditions

Malaria

Phase 2

Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.

TerminatedNCT00739206

Start: 2008-08-31End: 2009-06-30Updated: 2010-06-16

Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria

TerminatedNCT01445938

Start: 2011-10-31End: 2012-01-31Updated: 2012-12-13

Related Papers

Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients.

2017-05-047 citations

SAFETY AND EFFICACY OF SAR97276A FOR TREATING MALARIA: TWO OPEN-LABEL MULTICENTER PHASE II CLINICAL STUDIES IN AFRICAN CHILDREN AND ADULTS

BMJ Global Health2017-02-01